RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. - Wikidata - awgldk - TriplyDB

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

http://www.wikidata.org/entity/Q44596273

about

Targeting heart failure with preserved ejection fraction: current status and future prospects The cardiac enigma: current conundrums in heart failure research Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Targets for therapy in sarcomeric cardiomyopathies Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm Diastolic dysfunction Diabetic cardiomyopathy: where we are and where we are going.Update on ranolazine in the management of angina.Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Novel aspects of excitation-contraction coupling in heart failure.Targeting cardiomyocyte Ca2+ homeostasis in heart failure.Effect of late sodium current inhibition on MRI measured diastolic dysfunction in aortic stenosis: a pilot study.What Is the Evidence That the Tissue Doppler Index E/e' Reflects Left Ventricular Filling Pressure Changes After Exercise or Pharmacological Intervention for Evaluating Diastolic Function? A Systematic Review.Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women Two Distinct Responses of Left Ventricular End-Diastolic Pressure to Leg-Raise Exercise in Euvolemic Patients with Exertional Dyspnea.Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy.Pre-clinical diastolic dysfunction Heart failure with preserved ejection fraction in the elderly: scope of the problem.Newest additions to heart failure treatment.Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function Heart failure with preserved ejection fraction: uncertainties and dilemmas.The late sodium current in heart failure: pathophysiology and clinical relevance.Heart Failure with Preserved Ejection Fraction in Older Adults.Targets for Heart Failure With Preserved Ejection Fraction.Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death.Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure.Functional Studies of Sodium Channels: From Target to Compound Identification.Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Myocardial reverse remodeling: how far can we rewind?Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.Metabolic support for the heart: complementary therapy for heart failure?Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction.Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction.

P2860

Q26752956-B980C58B-FC7B-419A-ACA7-E18242DEDB81 Q26766151-3934C061-E665-4BF3-B37B-7BD8902923E5 Q26775037-B018CED9-6C6D-4ADA-B857-D8A5F7A8F32A Q26785931-CB6BFAC1-29B4-4B77-9D1A-B4FE2DF62CA6 Q27027023-4602CA07-31CD-4258-BA61-EC7E329FEC2F Q28077186-1B7C5709-D1B1-4D19-9F35-20687DCD3441 Q28087715-F8A1E0C7-5EE0-4D10-B437-C8E75D2B0D7C Q33690717-AD8D09D5-AFD5-48EC-A895-C814D7F5E7D5 Q33831222-444502BE-262C-4964-8162-3ABFE3B165F6 Q33885952-39206515-E397-4D67-A093-68B2AE2CB1ED Q33916951-957D3EAB-A34C-4C1E-BC9A-BC966A354DBA Q34375466-0E5A2A97-0544-4FD7-ABC4-AA987BB2B247 Q34652710-990BFEA0-BB92-4E80-AB54-F0BD985CFDBF Q35763705-F3DF8D06-1BA2-4815-9AF6-9521F54161FA Q35915087-4F7C70A4-3873-496F-9E0B-D958A72F56BC Q36309692-A4452BCB-94D3-4322-97AD-E7044C66CEF6 Q36760329-02794321-5762-40F5-9DA7-7F7075597AD5 Q36895814-06D8F559-1253-4680-B6E2-72CE2F46091E Q36964640-EC318CAC-CA5F-4144-8775-849B5BF0ED8E Q37374476-42AFFB4D-6269-4A7D-B8A2-1AD66F3FE4F7 Q37603551-D38A67EA-F3B1-49EE-AF3E-00A2B734A3CB Q37633991-34A401CF-5F43-4894-87F2-3965DACEBE66 Q38225739-2B53B69D-DDE6-48E0-B283-6DD86A65DBEC Q38377198-25B8CEF4-2F52-485B-AF52-6699C5514AD8 Q38529003-58F99269-2CF3-423C-8066-E0C372A8972D Q38611594-6E31FC68-5881-4A25-972F-1229B3BB6629 Q38672337-0DA62682-971D-4BE0-A1D0-037C7F8FB90D Q38688194-1D47DF89-98AB-430D-B84C-4D066A09B4E4 Q38699105-FFBD5A5F-74E7-459A-B1A4-96D9655F1096 Q38725641-475210AE-6813-4F40-A6FF-7F971BB6D680 Q38726402-DD3CD742-C8F9-47AC-B3EB-C8D0FE25E6D6 Q38743215-918D94CA-D866-457F-AC1F-B5A63E4B9363 Q38780883-6185C156-28B1-460C-AD89-7331F1BEEE54 Q38813373-E0DA274A-FE65-493F-AA84-42CC60F559E9 Q38998576-765C7A6B-90DD-4B26-BBE1-22CF3AFDC188 Q39397055-A9C693EA-2344-466B-8E77-A6B96F4794B3 Q39401767-CE73A11A-2912-41BE-AEFA-26CAD5A202D8 Q41297700-B4E8D11A-416E-4394-8BA3-175AAD606D8B Q42393093-CB73245B-696C-4304-A9EF-FB992DE59077 Q47981829-7DE43483-A26C-4BF3-8CD8-ED4C9F64105A

P2860

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.

http://www.wikidata.org/entity/Q44596273

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@en

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@nl

type

label

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@en

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@nl

prefLabel

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@en

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@nl

P1433

Q44596273-79DB0503-4AEA-46CD-ADA4-8DB40059AADC

P1476

Q44596273-37E81EFF-1FDD-4DC1-91BF-EDE5951D57F8

P2093

Q44596273-0529B6D7-F39B-43D9-81DB-DB779A359E0A

Q44596273-08245C9E-7783-4160-8C13-D28BF9AAEA7A

Q44596273-0B39FE5D-DE50-4774-B617-AE09D3B7E407

Q44596273-422AF6D6-3BB1-4551-B332-9A8148023A74

Q44596273-5976FCD9-4F9C-4A35-9AF7-F88DDC606135

Q44596273-5D4639B6-448D-4E3A-8D88-124A9DA8FB02

Q44596273-76876EDF-D0A7-4BDB-84DC-282A485B7089

Q44596273-ABCC5435-9B14-4CD9-95D8-A283597CEFF3

Q44596273-D736C207-CDB2-4895-85E7-0D96BA60AD8E

P304

Q44596273-981A7154-4AC6-4D08-B317-8C871EE5597A

P31

Q44596273-074318DE-C9A4-4441-B303-DB1A6FD4B87A

P356

Q44596273-178E7BAA-8C24-46B8-9223-E0E7C33C6B98

P433

Q44596273-9EC8A6C6-1205-4FD9-AC72-C82313CF54B0

P478

Q44596273-865EE881-6363-4335-B967-00BC27E4A986

P50

Q44596273-07EE831B-FB0B-4237-A6E8-94267F13A751

Q44596273-A45A371F-41B2-45F1-9798-A815C85ABB8B

P577

Q44596273-79AFF2F1-874C-4B27-9308-3BF61819817E

P5875

Q44596273-021A8F77-1D08-432F-B8D9-E05FF9CA2392

P698

Q44596273-F5C4BABC-3DAA-4EA0-BF0E-B1D52961C66E

P859

Q44596273-8409D2A0-EAF5-4EDA-93BE-A209248ADE69

P921

Q44596273-32DEF39A-BFCD-4756-A712-1FE33073025E

Q44596273-9F405DCC-1B67-4CBA-BE2C-401FDA71E0AA

Q44596273-B9EB8CAA-491F-4586-82BA-A2520D3A5B09

P356

J.JCHF.2012.12.002

P1433

JACC: Heart Failure

P1476

RAnoLazIne for the treatment o ...... LI-DHF proof-of-concept study.

@en

P2093

Beth Layug

http://www.w3.org/2001/XMLSchema#string

Christian Lang

http://www.w3.org/2001/XMLSchema#string

Claudius Jacobshagen

http://www.w3.org/2001/XMLSchema#string

Ewa Karwatowska-Prokopczuk

http://www.w3.org/2001/XMLSchema#string

Frank Edelmann

http://www.w3.org/2001/XMLSchema#string

Julia Sander

http://www.w3.org/2001/XMLSchema#string

Lars S Maier

http://www.w3.org/2001/XMLSchema#string

Luiz Belardinelli

http://www.w3.org/2001/XMLSchema#string

Stella Lee

http://www.w3.org/2001/XMLSchema#string

P304

115-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCHF.2012.12.002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257745893

http://www.w3.org/2001/XMLSchema#string

P698

24621836

http://www.w3.org/2001/XMLSchema#string

P859

Collaborative Research Centre (CRC) 1002: "Modulatory Units in Heart Failure"

P921